Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixivaptan long-term safety in ADPKD
NCT05208866Phase 3Terminated
- Sponsor
- Palladio Biosciences
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Palladio Biosciences. Primary endpoint: Number of Participants Who Develop Serum ALT Levels >3 × ULN Related to Lixivaptan and Resulted in Discontinuation at 120 days. Started Feb 2022; status: terminated.
02
Drugs
lixivaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT05208866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208866.